Afya Limited Releases 2024 Sustainability Report
The document, which presents Afya's trajectory throughout 2024, follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainable Development Goals (SDGs). It also reports specific indicators from the Sustainability Accounting Standards Board (SASB) and elements of the International Integrated Reporting Council (IIRC). The sustainability report contains some of the results of the fifth Greenhouse Gas (GHG) Emissions Inventory. Both of which have undergone individual audits by KPMG. The report is divided into two publications a narrative document and a technical annex in Excel format, which addresses all GRI and SASB indicators.
Afya's 2024 Sustainability Report is available at: https://ir.afya.com.br/annual-report/
About Afya Limited (Nasdaq: AFYA, B3: A2FY34)
Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250721441017/en/
Contacts
Investor Relations Contact:Afya Limitedir@afya.com.br
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial
AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS) for those with first-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). According to the final analysis of the randomised Phase III trial, FLAURA2, it demonstrated a consistent survival benefit, echoing interim OS outcomes and building upon the earlier reported longest median progression-free survival (PFS) data for this setting. The combo showed OS improvements in the open-label, global, multi-centre trial when compared against Tagrisso as a single agent for this patient group. Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen. The chemotherapy included pemetrexed at a dosage of 500mg/m² and either cisplatin at 75mg/m² or carboplatin (AUC5) administered every three weeks for a total of four cycles. After completing the cycles, the treatment continued with Tagrisso alongside maintenance doses of pemetrexed, also given every three weeks. A total of 557 subjects were enrolled in the trial in more than 150 centres across over 20 nations, including in Asia, Europe, South America, and the US. PFS is the primary endpoint of the trial. The combination therapy's safety profile remained manageable, aligning with known profiles of the individual medicines. According to the company, the trial recorded higher adverse event rates in the combination arm, attributed to expected chemotherapy-related effects. Discontinuation rates due to adverse events remained low. These findings are set to be presented at an upcoming medical meeting and will be communicated to global regulatory bodies. AstraZeneca oncology haematology R&D executive vice-president Susan Galbraith said: 'These exciting overall survival results add to the extensive evidence supporting Tagrisso as the backbone therapy in EGFR-mutated lung cancer, demonstrating that Tagrisso plus chemotherapy can significantly extend survival in the first-line advanced setting, in addition to prior trials showing survival benefits as monotherapy in both early stage and advanced disease.' More than 80 nations, including the European Union (EU), the US, Japan, and China, have currently approved Tagrisso + chemotherapy based on the FLAURA2 trial data. In 2023, AstraZeneca reported positive outcomes from the ADAURA Phase III trial of Tagrisso in the adjuvant treatment of individuals with Stage IB, II, IIIA EGFRm NSCLC. "AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
a day ago
- Medscape
Role of GLP-1 Drugs in Psoriasis and PsA Is Debated
BOGOTÁ, Colombia — Most dermatologists and rheumatologists agree that GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, powerful antidiabetes and weight-loss drugs, have the potential to help some patients with psoriasis and psoriatic arthritis (PsA). Besides mitigating obesity, an established risk factor for psoriasis and PsA, GLP-1 drugs have shown promise in improving psoriasis symptoms and are associated with a lower risk for cardiovascular events, for which people with psoriasis and PsA are at increased risk. Some researchers predict that the drugs will prove to have immunomodulatory effects and become an important addition to current treatments for psoriasis and PsA, even in patients without obesity or diabetes. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting and Trainee Symposium, investigators with the GRAPPA dove into hours' worth of discussions and debates about a class of drugs whose emergence Artie Kavanaugh, MD, professor of medicine at the University of California, San Diego, described as a possible 'watershed moment' for the field, akin to the advent of biologic therapies in the 1990s. But with evidence still sparse in patients with psoriatic disease and ancillary concerns about access, cost, patient selection, and physician confidence in prescribing, there was little agreement as to how, whether, or when these drugs should be integrated into clinical practice. A GLP-1 Pioneer Endocrinologist Daniel J. Drucker, MD, professor in the Department of Medicine's Division of Endocrinology, University of Toronto, Ontario, Canada, who discovered some key biological actions of the hormone GLP-1 in the 1980s and '90s, kicked off the conference with a video presentation affirming GLP-1 RAs potential as immunoregulatory agents with anti-inflammatory activity beyond their well-documented effects on body weight. In a 2023 trial of semaglutide in patients with obesity who did not have diabetes, Drucker noted prevention of cardiovascular events and death was seen as independent of weight loss. Similarly, Drucker said, a recent trial in people with metabolic liver disease saw improvements associated with semaglutide that were independent of weight loss. With psoriasis and PsA, randomized controlled trial evidence has yet to support weight-loss independent improvements in symptoms. However, this may soon change: In two separate trials, Eli Lilly is studying a combination of tirzepatide and the interleukin-17A antagonist ixekizumab in patients with overweight or obesity and psoriasis or PsA. The trials will wrap up next summer. Results from trials of GLP-1 inhibitors in nonobese populations, including cohorts of people with Alzheimer's disease, stand to shed further light on their anti-inflammatory effects outside the context of weight loss, Drucker said. 'These medicines are diversifying. We're going to see a wave of new molecules and new indications to treat inflammation,' he predicted, including that of skin, joints, and bone. Still, Drucker cautioned, the drugs 'are not magic bullets, and each condition will need to be assessed on its own.' Real-World Experience From Latin America In a subsequent talk, Enrique Soriano, MD, head of rheumatology at the Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, presented a real-world perspective from Latin America, where GLP-1 drugs are approved in most countries for diabetes or obesity — but still not easy to access and far from becoming a routine part of any rheumatologist's or dermatologist's daily practice. 'We all know that obesity increases the risk of developing psoriatic arthritis in psoriasis patients,' Soriano said — and that weight loss can decrease that risk. 'We also know that treatment response is lower in PsA patients with obesity,' he said. 'But the question for us is whether this drug [class] can improve symptoms and inflammation in our patients and whether this improvement, if it happens, is related to the weight loss or is an independent effect.' Soriano presented a retrospective review from his institution's service of 6800 patients with psoriasis (mostly mild) and 488 with PsA. In each group, just over 1% of patients were taking a GLP-1 RA for obesity, diabetes, or both. While acknowledging the limitations of his study's retrospective design, Soriano noted that 'there was no report of any improvement or change in the skin involvement, and there was also no record of any change in their joint symptoms after starting these drugs.' Soriano also conducted a survey of rheumatologists across several countries in Latin America and found that under a third said that they had encountered a patient whom they thought could benefit from the addition of a GLP-1 drug, while fewer than 10% said that they would feel confident prescribing one. More than half said that if they did think a patient could benefit, they would refer that person to a specialist, such as an endocrinologist. Dermatologist Describes Current Data as 'Weak' Anthony Fernandez, MD, PhD, director of medical and inpatient dermatology at the Cleveland Clinic, Cleveland, praised GLP-1 RAs as 'fascinating medications' with 'a very attractive adverse event profile.' Fernandez cited studies dating back over a decade in which use of these medications has been shown to improve psoriasis. 'And we have some data to suggest that the mechanism…is not entirely related to weight loss. In fact, there's data to support that these medications affect psoriasis-relevant immune pathways. So, in that way, they share similarities with many of the systemic medicines that we already prescribe to treat psoriasis.' Still, Fernandez cautioned, 'The data right now is really weak,' limited to small studies and randomized trials enrolling mostly men. While a few patients in these studies saw dramatic improvements in psoriasis after starting these drugs, 'the reality is that most have, at best, a modest improvement,' he said, 'certainly nowhere near the improvement we are used to seeing' from targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs). Moreover, he said, some patients enrolled in the studies were effectively treatment naive. 'That raises a critical question about whether or not a patient [on ts- or bDMARDs] would actually see any further improvement adding GLP-1 RAs,' he said. Fernandez said he thought that dermatologists can safely prescribe and manage GLP-1 therapies. The bigger question is whether they should. 'My opinion is no,' he concluded. 'There will be rare patients who are obese and or have type 2 diabetes and either fail or have a contraindication to all the great systemic medicines we already have available to us. And in those patients, a trial of a GLP-1 RA would seem to be reasonable. But personally, I think we need much, much better data for recommendations concerning general use by dermatologists.' During a question-and-answer period after Soriano's and Fernandez's presentations, other physicians shared their experiences and practical concerns about insurance approvals, referrals, and whether most dermatologists and rheumatologists were simply too busy to manage all the comorbidities of chronic immune-mediated disease for their patients. Some shared anecdotes about patients whose disease had improved after treatment with GLP-1 RAs, including in the absence of other systemic therapies. Patients Intrigued — but Share Clinician's Caution At the same session, Suzanne Grieb, PhD, a patient research participant (PRP) with GRAPPA and assistant professor at Johns Hopkins University, Baltimore , presented results from a survey of her fellow GRAPPA PRPs about their experiences and interests regarding GLP-1 drugs. None of the 11 respondents reported having been prescribed the medications. 'The majority of us described our psoriatic disease as mostly manageable with our current treatment,' Grieb, who has PsA, told the conference. However, that did not mean they weren't curious about GLP-1s. Grieb's survey revealed that while all participants were aware of the importance of exercise and healthy weight in disease management, many continued to struggle with both. Few reported having spoken with their providers about specific interventions. While three respondents expressed interest in taking GLP-1s, they were uncertain whether they would be able to access them. Patients 'are interested in GLP-1s' impact on our psoriatic disease, but also on other elements of our health, thinking more holistically [about] the benefits that could be achieved through these medications,' Grieb said. But the respondents in her survey also reported concerns about adding medications and 'the potential for having to take this medication for the rest of our lives.' In an interview after her presentation, Grieb elaborated on her personal perspective. 'I don't meet the requirement for obesity,' she said. 'But I'm overweight, and I could probably benefit from a GLP-1. Without clear weight-related indications, it's hard, perhaps to be able to justify prescribing it if it's not going to be available. So it's a hard conversation [for clinicians] to bring up with their patients.'
WebMD
a day ago
- WebMD
How I Prep for Big Life Moments When My Skin Isn't Cooperating
Last month, I flew to Brazil for a trip I'd been planning for months. It was meant to be a getaway full of joy, beach days, sightseeing, and reconnecting with friends. What I didn't plan for was having an eczema flare-up days before my flight. The timing couldn't have been worse. My skin was irritated and inflamed, and I was concerned about what a long flight, sun exposure, and unfamiliar products might do to my already flaring skin. I thought about canceling. But I also thought about how many moments I've missed before because of my skin. This time, I didn't want eczema to win. So I made a plan. Prepping for big life moments when my skin isn't cooperating starts with adjusting my mindset. I remind myself that I deserve to show up, even if my skin isn't perfectly calm. I talk to myself like I would to a friend, gently but firmly, and I give myself permission to enjoy what's in front of me, even if I don't feel 100%. Then I go into logistics mode. I pack backup moisturizers, barrier creams, and anything I know will bring me comfort. I also bring clothing that makes me feel confident and protected, like soft fabrics, breathable materials, and silhouettes I can move in without friction. For that Brazil trip, I brought my full skin care kit in a carry-on just in case my luggage got lost. I kept an antihistamine on hand and made sure I stayed hydrated during the flight. I also booked accommodations with laundry access so I could control what detergents were used. On the day of big events like weddings, presentations, or reunions, I give myself extra time to get ready. Not to cover anything up, but to make space to move at my own pace. I prep my skin carefully, use a little makeup if it feels good, and choose an outfit that lets me feel free. That trip to Brazil turned out to be beautiful. I didn't hide my skin. I showed up in sleeveless tops, took photos on the beach, and danced through the heat. I had moments of discomfort, yes. But I also had moments of ease, laughter, and connection. And those are what I remember most. Living with a skin condition doesn't mean you have to sit life out. It just means you learn how to show up differently, with extra care, more patience, and a lot of resilience.
